Nature Communications (Nov 2019)
On-target restoration of a split T cell-engaging antibody for precision immunotherapy
- Agnes Banaszek,
- Thomas G. P. Bumm,
- Boris Nowotny,
- Maria Geis,
- Kim Jacob,
- Matthias Wölfl,
- Johannes Trebing,
- Kirstin Kucka,
- Dina Kouhestani,
- Tea Gogishvili,
- Bastian Krenz,
- Justina Lutz,
- Leo Rasche,
- Dirk Hönemann,
- Hannes Neuweiler,
- Julia C. Heiby,
- Ralf C. Bargou,
- Harald Wajant,
- Hermann Einsele,
- Gert Riethmüller,
- Gernot Stuhler
Affiliations
- Agnes Banaszek
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Thomas G. P. Bumm
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Boris Nowotny
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Maria Geis
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Kim Jacob
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Matthias Wölfl
- University Clinic Würzburg, Children’s Hospital, Pediatric Oncology, Hematology and Stem Cell Transplantation
- Johannes Trebing
- University Clinic Würzburg, Department of Internal Medicine II, Division of Molecular Internal Medicine
- Kirstin Kucka
- University Clinic Würzburg, Department of Internal Medicine II, Division of Molecular Internal Medicine
- Dina Kouhestani
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Tea Gogishvili
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Bastian Krenz
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Justina Lutz
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Leo Rasche
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Dirk Hönemann
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Hannes Neuweiler
- Department of Biotechnology and Biophysics, University Würzburg
- Julia C. Heiby
- Department of Biotechnology and Biophysics, University Würzburg
- Ralf C. Bargou
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Harald Wajant
- University Clinic Würzburg, Department of Internal Medicine II, Division of Molecular Internal Medicine
- Hermann Einsele
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- Gert Riethmüller
- Ludwig-Maximilians-University, Institute for Immunology
- Gernot Stuhler
- University Clinic Würzburg, Department of Internal Medicine II, Hematology and Oncology
- DOI
- https://doi.org/10.1038/s41467-019-13196-0
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 10
Abstract
The restriction of appropriate tumour-specific antigens is a current limitation for T cell-engaging immunotherapy. Here, the authors have designed a new system constituted by two halve antibodies, which engage T cells once binding to two different antigens, to specifically eliminate double positive cells in preclinical leukemia and breast cancer mouse models.
